DALLAS, May 14, 2024
/PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical
biotechnology company developing gene therapies for inherited
retinal diseases and age-related macular degenerations (AMD), today
announced the appointment of Khandan
Baradaran, PhD, as Senior Vice President of Regulatory and
Quality. Dr. Baradaran brings nearly two decades of extensive
experience in manufacturing and regulatory review of gene therapy
products, including regulatory and chemistry, manufacturing, and
controls (CMC) experience.
"Khandan's experience leading quality and compliance for rare
genetic disease biopharmaceutical companies will be valuable as we
continue to advance our versatile MCO platform, including MCO-010,
which is driving our expanding pipeline of programs. This
appointment supports the continued advancement of our
mutation-agnostic therapies to restore vision in millions of people
blinded by retinal diseases and further highlights our continued
growth as a company," said Sulagna
Bhattacharya, Co-Founder and Chief Executive Officer of
Nanoscope.
"I am honored to join the highly motivated team at Nanoscope in
the development of its novel approach to treating retinal
degenerative diseases," said Dr. Baradaran. "Following the
impressive durable efficacy and safety results from the randomized
control trial in retinitis pigmentosa, I eagerly anticipate
contributing to Nanoscope's advancement as we navigate forthcoming
regulatory milestones and prepare for commercial readiness."
Dr. Baradaran was most recently Vice President of Regulatory CMC
at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company
involved in the research and development of novel products for the
treatment of rare and ultra-rare genetic diseases. Previously, Dr.
Baradaran was Vice President and Head of Quality at Dimension
Therapeutics, a gene therapy company focused on developing novel
treatments for rare diseases. Prior to this, she held CMC and
Regulatory positions at Biogen, Novartis, and Dyax. She holds a PhD
in Virology from Harvard University and
a BA in Molecular Biology from Wellesley
College.
About Nanoscope Therapeutics Inc.
Nanoscope
Therapeutics is developing gene-agnostic, sight-restoring
optogenetic therapies for the millions of patients blinded by
inherited retinal diseases, for which no cure exists. The company's
lead asset, MCO-010, recently announced the 100-week data from the
RESTORE Phase 2b/3 multicenter,
randomized, double-masked, sham-controlled clinical trial in the
U.S. for RP (NCT04945772). The company has also recently completed
the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with
Stargardt disease (NCT05417126). MCO-010 has received FDA
fast-track designations and FDA orphan drug designations for both
RP and Stargardt disease. Preclinical assets include non-viral
laser-delivered MCO-020 gene therapy for geographic
atrophies secondary to AMD.
Investor Contact:
Argot Partners
212-600-1902
PR@nanostherapeutics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-appoints-khandan-baradaran-as-senior-vice-president-of-regulatory-and-quality-302143929.html
SOURCE Nanoscope Therapeutics